Advertisement
Singapore markets open in 6 hours 47 minutes
  • Straits Times Index

    3,300.04
    -3.15 (-0.10%)
     
  • S&P 500

    5,186.90
    +6.16 (+0.12%)
     
  • Dow

    38,869.53
    +17.26 (+0.04%)
     
  • Nasdaq

    16,340.80
    -8.45 (-0.05%)
     
  • Bitcoin USD

    63,260.82
    +54.40 (+0.09%)
     
  • CMC Crypto 200

    1,313.40
    -51.73 (-3.79%)
     
  • FTSE 100

    8,313.67
    +100.18 (+1.22%)
     
  • Gold

    2,322.50
    -8.70 (-0.37%)
     
  • Crude Oil

    78.64
    +0.16 (+0.20%)
     
  • 10-Yr Bond

    4.4490
    -0.0400 (-0.89%)
     
  • Nikkei

    38,835.10
    +599.03 (+1.57%)
     
  • Hang Seng

    18,479.37
    -98.93 (-0.53%)
     
  • FTSE Bursa Malaysia

    1,605.68
    +8.29 (+0.52%)
     
  • Jakarta Composite Index

    7,123.61
    -12.28 (-0.17%)
     
  • PSE Index

    6,618.58
    -33.91 (-0.51%)
     

Analysts Are Mostly Positive on Neurocrine Biosciences in August

Analysts Are Mostly Positive on Neurocrine Biosciences in August

In July 2018, the FDA approved AbbVie’s (ABBV) and Neurocrine Biosciences’ (NBIX) Orilissa for the treatment of women with moderate to severe endometriosis. Orlissa (elagolix) is the first and only GnRH (gonadotropin-releasing hormone) antagonist approved for the treatment of moderate-to-severe endometriosis pain in women.